To study the metabolism and production of angiotensin I, highly purified monoiodinated [ synthesized mainly by the kidneys, acts on renin substrate (angiotensinogen) to form the decapeptide angiotensin I (Ang I), which is then converted to the octapeptide angiotensin II (Ang II) by angiotensin converting enzyme (ACE). All these components of the renin-angiotensin system are pres-
I] angiotensin I and unlabeled angiotensin I were similar for the two peptides. The regional extraction ratio of [

I2S I]angiotensin I was 47±4% (mean±SEM)
across the forearm, 59±3% across the leg, 81±1% across the kidneys, and 96±1% across the hepatomesenteric vascular bed. These results were not different from those obtained for infused unlabeled angiotensin I. Despite the rapid removal of arterially delivered angiotensin I, no difference was found between the venous and arterial levels of endogenous angiotensin I across the various vascular beds, with the exception of the liver where angiotensin I in the vein was 50% lower than in the aorta. Thus, 50-90% of endogenous angiotensin I in the veins appeared to be derived from regional de novo production. The blood transit time is 0.1-0.2 minute in the limbs and in the kidneys and 0.3-0.5 minute in the hepatomesenteric vascular bed. This is too short for plasma renin activity to account for the measured de novo angiotensin I production. It was calculated that less than 20-30% in the limbs and in the kidneys and approximately 60% in the hepatomesenteric region of de novo-produced angiotensin I could be accounted for by circulating renin. These results indicate that a high percentage of plasma angiotensin I may be produced locally (i.e., not in circulating plasma). (Hypertension 1990;15:44-55) R enin (EC 3.4.23.15), an aspartyl protease synthesized mainly by the kidneys, acts on renin substrate (angiotensinogen) to form the decapeptide angiotensin I (Ang I), which is then converted to the octapeptide angiotensin II (Ang II) by angiotensin converting enzyme (ACE). All these components of the renin-angiotensin system are pres-depends on locally synthesized rather than systemically delivered renin.
Renin is synthesized by various tissues apart from the kidney, and there is evidence for local angiotensin generation in some of these tissues. 2 - 4 In culture, bovine and canine vascular smooth muscle cells and bovine endothelial cells synthesize Ang II and secrete this peptide into the medium. 56 Isolated rat mesenteric arteries, when perfused with solutions free of renin and renin substrate, release Ang II into the perfusate, 7 and in similar experiments, isolated rat hindlegs were found to release both Ang I and Ang II. 8 Thus, part of Ang I and Ang II circulating in plasma may have been generated locally in the interstitium or in the cells of vascular tissue, and it has been postulated that a vascular renin-angiotensin system is important for the regulation of vascular tone and the maintenance of hypertension. 9 -12 The production rate of angiotensins in different vascular beds cannot be simply derived from the regional blood flow and the arteriovenous concentration gradient because a high rate of production may be matched by a high rate of metabolism. Studies using tracer amounts of radiolabeled angiotensins for measurement of Ang I to II conversion and Ang I and II degradation are scarce because it is difficult to measure the angiotensins separately from their metabolites and also because of the instability of some earlier radiolabeled iodine angiotensin preparations. More recent studies in dogs with highly purified monoiodinated [ The present study was undertaken to explore the possibility of measuring the rate of metabolism of Ang I 
Preparation of Angiotensin Antisera
Ang I and Ang II antisera were produced in New Zealand White rabbits by intracutaneous injections of 330 /xg of either Ang I or Ang II coupled to BSA with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HC1 and suspended in Freund's complete adjuvant. Booster injections of the conjugates suspended in Freund's incomplete adjuvant were given at 4-week intervals. The Ang I antiserum was used in the radioimmunoassay in a final dilution of 1^250,000. This antiserum gave a B/Bo ratio of 0.9 at 2 fmol Ang I and a B/Bo ratio of 0.5 at 20 fmol Ang I. The antiserum also reacted (100%) with Ang-(2-10) nonapeptide but did not react (less than 0.1%) with Ang II, Ang III, Ang-(3-8) hexapeptide, or Ang-(4-8) pentapeptide. The Ang II antiserum was used in a final dilution of 1:200,000. It gave a B/Bo ratio of 0.9 at 1.5 fmol Ang II and a B/Bo ratio of 0.5 at 16 fmol Ang II. This antiserum also reacted with Ang III (55%), hexapeptide (73%), and Ang-(4-8) pentapeptide (100%) but virtually not with Ang I (0.3%) and Ang-(2-10) nonapeptide (0.2%). The renin inhibitor CGP 29,287, in concentrations up to 100 /AM, did not react with either Ang I or Ang II antisera.
Blood Sampling
Blood for angiotensin measurements was rapidly (7-13 seconds) drawn with a plastic syringe containing the following inhibitors (0.5 ml inhibitor solution in 10 ml blood), 6.25 mM disodium EDTA, 1.25 mM 1,10-phenantroline, and 100 nM of the renin inhibitor CGP 29,287 (final concentrations in blood) and transferred into prechilled polystyrene tubes. These inhibitors were used to prevent Ang I generation, Ang I to II conversion, and Ang I and II degradation during blood collection and handling of the samples. The blood samples were centrifuged at 3,000g for 10 minutes at 4°C. Plasma was stored at -70° C, extracted within 2 days, and assayed within 2 weeks. The renin inhibitor CGP 29,287 is a renin substrate analogue. At a concentration of approximately 1 nM, it inhibits PRA by 50%. 17 We chose to use the inhibitor in a final concentration of 100 nM on the basis of previous experiments in which we added the inhibitor in concentrations ranging from 0.1 to 1,000 nM to a plasma sample with normal PRA (12 pmol/ 1/min) and to plasma samples with elevated PRA (77 and 260 pmol/1/min). Ang I formation during incubation was inhibited by 98% at 37° C and by 100% at 20° C, both at an inhibitor concentration of 100 nM.
Blood for PRA measurements was collected into polystyrene tubes containing EDTA (0.2 ml disodium EDTA in 10 ml blood, final concentration 6.25 mM). The samples were centrifuged at room temperature at 3,000g for 10 minutes, and plasma was stored at -20° C.
Extraction of Angiotensins
Solid phase extraction cartridges (Sep-Pak C18, Waters Chromatography Div.) were conditioned with 4 ml methanol and then equilibrated two times with 4 ml cold water. Thawed plasma samples (2 ml) were applied to the cartridges. After the bound peptides were washed two times with 4 ml cold water, they were eluted with 2 ml methanol and collected into conical polypropylene tubes. The methanol extracts were evaporated at 4° C with a Savant Speed Vac concentrator (Savant Instrs., Farmingdale, New York). Recovery of labeled and unlabeled Ang I and II from the Sep-Pak cartridges was 95-98%.
Separation of Angiotensins by High-Performance Liquid Chromatography
Separation of the peptides in the methanol extracts was performed with HPLC by the method of Nussberger et al 18 with some modifications. We used a reversed-phase Nucleosil C18 steel column of 250x4.6 mm and 10 pm particle size equipped with a directconnect guard column (Alltech, Eke, Belgium). The HPLC equipment consisted of an LKB 2150 pump, a 2152 controller, a 2122 fraction collector, and a 2155 column oven (LKB, Bromma, Sweden). Samples were injected with a Rheodyne 7125 injection valve equipped with a 250 /xl loop (Rheodyne Inc., Cotati, California). Mobile phase A was 0.085% orthophosphoric acid containing 0.02% sodium azide (pH 2.33). Mobile phase B was methanol. The flow was 1 ml/min, and the working temperature was 45° C. The column was calibrated with pure Iodine-125-labeled standards of Ang I and Ang II and with unlabeled Ang I, Ang II, Ang III, and some of their metabolites. The vacuum-dried plasma extracts were dissolved in 100 /A HPLC solvent (65% A/35% B, vol/vol), centrifuged, and injected with a 100 fd Hamilton syringe (No. 1710, Hamilton, Bonaduz, Switzerland). Elution was performed as follows: 65% A/35% B from 0 to 9 minutes followed by a linear gradient to 45% A/55% B until 18 minutes. The eluate was collected in 0.5-minute fractions into polystyrene tubes coated with BSA. 
Radioimmunoassay of Angiotensins
The dried HPLC fractions were dissolved in 0.25 M Tris buffer, pH 7.4, containing 0.35% BSA and 0.02% sodium azide. They were then incubated with [ 
Measurement of Plasma Renin Activity
PRA was measured by incubation of the plasma at 37° C for 0, 15, 30, and 60 minutes. During the 60-minute incubation period, pH varied from 7.1 at t=0 minutes to 7.5 at t=60 minutes. PRA measurements under these conditions gave results not different from measurements in the presence of 100 mM imidazol buffer, pH 7.4. With this buffer, pH remained 7.4 during incubation. To prevent Ang I to II conversion, Ang I degradation, prorenin-renin conversion, and bacterial growth, the following mixture of inhibitors was added to plasma before incubation (35 fil inhibitor solution/ml plasma): 5 mM disodium EDTA, 3.4 mM 8-hydroxyquinoline sulfate, 2.4 mM phenylmethylsulfonyl fluoride, 2.2 nM aprotinin, and 1 mg/ml neomycin sulfate (final concentrations in plasma).
The inhibitors do not interfere with the reaction of renin with substrate. The kinetic constants, V max and K m , of this reaction are not modified when these inhibitors are added to mixtures of highly purified human renin and human substrate. The measured levels of PRA are not different from those calculated from these kinetic constants and from the concentrations of renin and substrate measured in plasma.
Ang I that was generated during incubation was quantitated by radioimmunoassay. Ang I generation in the PRA assay was linear in the first 30 minutes of incubation, but in some samples, the rate of Ang I generation was somewhat lower in the following 30 minutes. Only the first linear part of the Ang I generation curve was used for calculation of PRA. The recovery of renin or Ang I added to plasma before assay was 98-100%.
PRA is expressed as picomoles Ang I per liter plasma per minute of incubation (pmol/1/min). The normal level of PRA in antecubital venous plasma was 12.7 pmol/1/min (geometric mean), range 2.3-66.7 pmol/ 1/min (n=74). This is in close agreement with the results obtained by the "antibody-trapping" technique.
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Measurement of Renal Plasma Flow
Renal plasma flow was determined by measurement of the clearance of [ 
Preparation of Radiolabeled Angiotensin I for Intravenous Infusion
Ang I was radiolabeled by the chloramine T method. 23 All solutions were made in sterile pyrogene free water. The whole procedure was carried out under aseptic conditions. In short, 4 nmol Ang I in 20 fjd of 0.25 M sodium phosphate buffer, pH 7.5, was mixed with 1 mCi (37 MBq) [ ]iodide and labeled peptide were separated on a 5x50 mm Dowex-AG-I-X8 column (50-100 mesh, Bio-Rad Labs., Richmond, California). Elution was carried out with 0.1 M acetic acid containing 0.1% human serum albumin. Labeled Ang I does not bind to the column under these conditions. Fractions of 0.5 ml were collected, and the fractions containing labeled peptide were pooled.
To obtain monoiodinated [ 
Subjects
Ten subjects with hypertension (four men, six women, mean age 48, range 26-67 years) were studied at the time they were undergoing renal vein sampling followed by renal angiography for diagnostic purposes. The renal vein renin ratio was normal (<1.5) as was the renal angiogram. Blood pressure in the outpatient clinic was repeatedly above 160/100 mm Hg despite antihypertensive medication. Routine urine analysis, serum creatinine, and serum electrolytes were normal, and the subjects were considered to have essential hypertension. Seven subjects received an infusion of [ . Two additional subjects with essential hypertension (one woman 47 years old and one man 58 years old) were studied at the end of a 24-hour period of intra-arterial blood pressure recording. Renal vein renin sampling and renal angiography had been performed some months before and were normal. These two subjects received an infusion of both [ I ] A n g I and Ang I.
All subjects received 5 ml Lugol's solution/day from 2 days before to 4 days after the angiotensin infusion. The subjects were treated with the ACE inhibitor captopril (50 mg p.o., b.i.d.). The infusion studies were performed 4-6 hours after administration of the morning dose of captopril.
Infusion Protocol
[ 125 I]Ang I was infused at a rate of approximately 3.0xlO 6 cpm/min, and Ang I at a rate of approximately 1.2 nmol/min for 20 minutes. An indwelling needle for blood sampling was placed in the antecubital vein of the left arm. After insertion of the catheters into the abdominal aorta and the inferior caval vein via the femoral artery and vein by the Seldinger technique, angiotensin was infused via the antecubital vein of the right arm. A blood sample was taken from the abdominal aorta before the infusion. Ten minutes after the infusion had been started, samples were taken from the aorta, the hepatic vein, and the antecubital vein of the left arm. In the following 10 minutes, a second and third series of samples were taken simultaneously from the aorta, the antecubital vein, and a renal vein, first from one kidney and then from the other. A sample from the femoral vein was taken shortly before discontinuation of the infusion. The arterial plasma levels of [ The two subjects studied some months after renal vein catheterization received an intravenous infusion of [ 125 I]Ang I and Ang I in one arm, and blood samples were taken from the brachial artery and the antecubital vein of the other arm before the infusion and at 10, 15, and 20 minutes after the start of the infusion. For measurement of the elimination halflife of the infused peptides, samples were taken from the brachial artery at the previously mentioned times after the infusion had been stopped.
Urinary excretion of radioactivity was followed over a period of 96 hours. Ninety percent of the administered radioactivity was excreted within 24 hours, and 98% was recovered in the 96-hour period. The calculated exposure to radioactivity was 0.24 fiGy (or 0.6 mrad) from the [ 24 The protocol was approved by the Hospital Ethical Review Committee.
Calculations
The regional extraction ratio of [ The single kidney net de novo production of Ang I is then obtained by multiplication of single kidney plasma flow by the renal venous plasma level of intrarenally de novo-produced Ang I.
Results
High-Performance Liquid Chromatography Separation of Angiotensin Peptides
Under the conditions specified in Methods, satisfactory separations were obtained between Ang I, Ang II, and their metabolites as well as their radiolabeled counterparts (Figure 1) . Apart from the metabolites shown in Figure 1 , we also tested [ Table 1 . Because of ACE inhibitor treatment, the infusions of Ang I did not result in a significant reduction of PRA. The preinfusion level of Ang I was therefore taken as a measure of the contribution of endogenous Ang I to the level of Ang I during infusion of this peptide. Thus, for calculation of the regional extraction of infused Ang I, the preinfusion level of Ang I was subtracted from the level during infusion. From measurements of the arterial and venous plasma levels of [ 125 I]Ang I and unlabeled Ang I, it appeared that during infusion of the two peptides the regional extraction ratios for labeled and unlabeled Ang I were not different (Figure 3) . In most patients, the plasma concentrations of [ I]Ang I and unlabeled Ang I fell monoexponentially after discontinuation of the infusion. Some curves, however, showed a delay. This delay can be explained, at least in part, by the passage time of blood from the infusion site to the sampling site, but the delay could also represent the exit of [ PRA and angiotensin levels vary widely among subjects with essential hypertension. This was also the case in our study. PRA in the aorta ranged from 3.8-122 pmol/1/min. The plasma levels of [ (Ang) 
Regional Production of Angiotensin I
In spite of the rapid extraction of arterially delivered Ang I, the arterial and venous plasma levels of endogenous Ang I across the kidneys and the limbs showed little difference ( Figure 5 ). The veinto-artery Ang I concentration ratio was 0.98±0.05 across the kidneys, 1.01 ±0.03 across the forearm, and 1.00±0.03 across the leg. Ang I concentration in the hepatic vein was lower than in the aorta. The veinto-artery Ang I concentration ratio across the hepatomesenteric vascular bed was 0.52±0.03. From these data and from the regional extraction ratio of Ang I, the venous concentration of Ang I derived from regional de novo production could be calculated. Figure 6 clearly illustrates the point that a high proportion of venous Ang I originated from regional de novo production. For the renal vascular bed, it was possible to calculate the net de novo production rate of Ang I because renal plasma flow was measured. Single kidney plasma flow was 0.283±0.020 1/min, and single kidney net de novo production of Ang I was calculated to be 7.1 pmol/min (geometric mean), range 2.4-29.5 pmol/min.
Contribution of Plasma Renin Activity to Regional Production of Angiotensin I
The mean transit time of blood is 0.1-0.2 minute in the kidneys and the limbs and 0.3-0.5 minute in the hepatomesenteric vascular bed. 25 -26 From this and the measured levels of PRA, we can calculate the contribution of circulating PRA to the total regional production of Ang I. In the classical concept of the reninangiotensin system, circulating renin should fully account for this production. The calculations, however, showed that circulating PRA only accounted for less than 20-30% of Ang I production in the kidneys, the forearm, and the leg. In the hepatomesenteric vascular bed, circulating PRA accounted for about 60% of the Ang I production in this region (Table 3) . The present study addressed the question whether in humans the rate at which Ang I is generated by the reaction of circulating renin with circulating renin substrate is sufficiently high to maintain the actual plasma level of Ang I in the face of the rapid metabolism of this peptide. We studied Ang I metabolism Ang I , at least in subjects on ACE inhibitor treatment. With such treatment, Ang I metabolism is mainly due to degradation into smaller inactive fragments. Apparently, there is little or no difference in the rate of degradation between labeled and unlabeled Ang I. Whether the conversion rates of the two peptides are also similar has to be established by measurements in subjects not on ACE inhibitor treatment.
Extraction of arterially delivered Ang I by the vascular beds we studied ranged from 47 to 96%. The plasma levels of ACE and angiotensinase activity are by far too low to account for the rapid removal of Ang I. Thus, it appears that most of Ang I metabolism takes place at the surface of blood vessels or in the vascular tissue. In studies in dogs, [ 125 I]Ang I was infused into the renal artery, and it was found that about 80% was removed during a single passage of blood through the kidney. 13 This was for the most part due to degradation rather than conversion. Our results in humans are in agreement with these data.
From the regional extraction ratios of Ang I and from the arteriovenous differences in Ang I, it was calculated that approximately 50-90% of Ang I in the regional veins was not derived from arterially delivered Ang I but from regional de novo production. In the dog, it was found that 70-80% of Ang I in the renal veins was derived from de novo produc- tion in the kidney, 13 which is similar to what we found for the human kidney.
With the exception of the hepatomesenteric vascular bed, where the plasma level of Ang I in the hepatic vein was found to be much lower than in the aorta, there was little or no arteriovenous difference in Ang I. Thus, the rapid removal of plasma Ang I was matched by a high rate of production. By taking into consideration the blood transit time in the various vascular beds, it can easily be seen that circulating levels of PRA were not sufficient to account for this high rate of Ang I production. The mean transit time of blood in the kidneys and the limbs is 0.1-0.2 minute or less. 25 - 26 From this and from the measurements of PRA, the extraction of arterially delivered Ang I, and the arteriovenous difference in the plasma levels of Ang I, it was calculated that less than 20-30% of Ang I produced in the kidneys, the forearm, and the leg could be accounted for by the generation of Ang I by circulating PRA (Table 3) . For the renal vascular bed, it was possible to calculate the net de novo production rate of Ang I because renal plasma flow was known. The single kidney intravascular plasma volume is approximately 40 ml.
25 From this and from the level of PRA in the renal vein, it was calculated that less than 10% of Ang I produced in the kidney could be accounted for by circulating PRA. The calculated contribution of PRA is a maximum value because it is quite likely that part of regionally produced Ang I is metabolized before it can reach the veins. The blood transit time in the hepatomesenteric vascular bed is 0.3-0.5 minute, 26 and in this region, the Ang I production could be largely accounted for by circulating PRA.
The conclusion of this study, that a high proportion of Ang I in plasma appears not to be generated by the action of circulating renin on circulating renin substrate, depends on the validity of using PRA in vitro as a precise measure of the generation of Ang I by plasma in vivo. We therefore performed the PRA assay at near physiological pH under conditions that did not cause denaturation of renin, activation of prorenin, and conversion and degradation of Ang I, and did not interfere with the reaction of renin with its substrate.
From the data presented in Table 2 , it is evident that a discrepancy exists between the [ The results of the present study add new evidence to previously published data supporting the hypothesis that a major fraction of Ang I in circulating plasma is produced locally rather than in circulating plasma itself. The local production of Ang I may ' 26 Three arterial samples were collected from the abdominal aorta during the steady-state phase: sample 1 simultaneously with the antecubital vein and hepatic vein samples, sample 2 simultaneously with a left or right renal vein sample, and sample 3 simultaneously with a renal vein sample on the opposite side. The femoral vein sample was taken immediately after aortic sample 3. The left and right renal vein levels of PRA and Ang I were averaged as were the two corresponding aortic levels of PRA. Ang I, angiotensin I; PRA, plasma renin activity. *«=5.
depend on synthesis of renin in situ. Binding or uptake of plasma renin or prorenin and subsequent activation of prorenin and local production of Ang I are other possibilities. Whatever the exact mechanism, vascular production of Ang I may contribute to the control of vascular tone, and this contribution may be independent, at least in part, of the circulating levels of renin and renin substrate.
